BACKGROUND: Given the malignant potential of main duct intraductal papillary mucinous neoplasm (M-IPMN), surgical resection is generally indicated. With regard to side-branch intraductal papillary mucinous neoplasm (SB-IPMN), resection vs. observation is a topic of debate. Further review of SB-IPMN is necessary to clarify appropriate management. The primary focus of this project is to determine the incidence of malignant final pathology for patients undergoing surgery for isolated SB-IPMN with non-malignant fine-needle aspiration (FNA) cytology. We also sought to describe the relationship between factors considered in the international consensus guidelines and final pathologic outcome. METHODS: The study is a retrospective review of all patients who underwent surgical resection for intraductal papillary mucinous neoplasm (IPMN) from 2002 to 2013 at our institution. Patients with a preoperative diagnosis of isolated SB-IPMN and FNA results for non-malignant cytology were selected among this surgical cohort for further analysis of preoperative clinical characteristics and outcomes. RESULTS: A total of 137 patients undergoing resection for IPMN were identified. Of these, 81 patients (59%) had a component of M-IPMN or invasive disease on FNA, leaving 66 (46%) patients with SB-IPMN and non-malignant cytology. Invasive adenocarcinoma was found in 8/66 (12%) patients and high-grade dysplasia (HGD) in 4/66 (8%) patients. The mean [SD] diameter of benign SB-IPMN was 2.0 cm [1.1] (range 0.3-5.7) vs. that of HGD/invasive disease which was 3.1 cm [1.3] (range 1.5-6.0; P = 0.014). Of the 12 patients found to have HGD or invasive disease, symptoms, mural nodules, and septations were found in 7 (58%), 5 (42%), and 6 (50%), respectively. Tumor staging were as follows: IA (2), IB (2), 2A (4), and 2B (1). CONCLUSION: With proper selection criteria, SB-IPMN is associated with a low rate of invasive pancreatic ductal adenocarcinoma at the time of resection. Nevertheless, given the demonstrated incidence of malignancy, appropriate operative candidates should undergo resection.
BACKGROUND: Given the malignant potential of main duct intraductal papillary mucinous neoplasm (M-IPMN), surgical resection is generally indicated. With regard to side-branch intraductal papillary mucinous neoplasm (SB-IPMN), resection vs. observation is a topic of debate. Further review of SB-IPMN is necessary to clarify appropriate management. The primary focus of this project is to determine the incidence of malignant final pathology for patients undergoing surgery for isolated SB-IPMN with non-malignant fine-needle aspiration (FNA) cytology. We also sought to describe the relationship between factors considered in the international consensus guidelines and final pathologic outcome. METHODS: The study is a retrospective review of all patients who underwent surgical resection for intraductal papillary mucinous neoplasm (IPMN) from 2002 to 2013 at our institution. Patients with a preoperative diagnosis of isolated SB-IPMN and FNA results for non-malignant cytology were selected among this surgical cohort for further analysis of preoperative clinical characteristics and outcomes. RESULTS: A total of 137 patients undergoing resection for IPMN were identified. Of these, 81 patients (59%) had a component of M-IPMN or invasive disease on FNA, leaving 66 (46%) patients with SB-IPMN and non-malignant cytology. Invasive adenocarcinoma was found in 8/66 (12%) patients and high-grade dysplasia (HGD) in 4/66 (8%) patients. The mean [SD] diameter of benign SB-IPMN was 2.0 cm [1.1] (range 0.3-5.7) vs. that of HGD/invasive disease which was 3.1 cm [1.3] (range 1.5-6.0; P = 0.014). Of the 12 patients found to have HGD or invasive disease, symptoms, mural nodules, and septations were found in 7 (58%), 5 (42%), and 6 (50%), respectively. Tumor staging were as follows: IA (2), IB (2), 2A (4), and 2B (1). CONCLUSION: With proper selection criteria, SB-IPMN is associated with a low rate of invasive pancreatic ductal adenocarcinoma at the time of resection. Nevertheless, given the demonstrated incidence of malignancy, appropriate operative candidates should undergo resection.
Authors: Klaus Sahora; Mari Mino-Kenudson; William Brugge; Sarah P Thayer; Cristina R Ferrone; Dushyant Sahani; Martha B Pitman; Andrew L Warshaw; Keith D Lillemoe; Carlos F Fernandez-del Castillo Journal: Ann Surg Date: 2013-09 Impact factor: 12.969
Authors: Camilo Correa-Gallego; Murray F Brennan; Yuman Fong; T Peter Kingham; Ronald P DeMatteo; Michael I DʼAngelica; William R Jarnagin; Peter J Allen Journal: Ann Surg Date: 2014-03 Impact factor: 12.969
Authors: M R Barron; A M Roch; J A Waters; J A Parikh; J M DeWitt; M A Al-Haddad; E P Ceppa; M G House; N J Zyromski; A Nakeeb; H A Pitt; C Max Schmidt Journal: J Gastrointest Surg Date: 2014-01-09 Impact factor: 3.452
Authors: R Matthew Walsh; David P Vogt; J Michael Henderson; KenZo Hirose; Travis Mason; Kalman Bencsath; Jeffrey Hammel; Nancy Brown Journal: Surgery Date: 2008-08-29 Impact factor: 3.982
Authors: Thomas Schnelldorfer; Michael G Sarr; David M Nagorney; Lizhi Zhang; Thomas C Smyrk; Rui Qin; Suresh T Chari; Michael B Farnell Journal: Arch Surg Date: 2008-07
Authors: Brian K P Goh; Damien M Y Tan; Mac M F Ho; Tony K H Lim; Alexander Y F Chung; London L P J Ooi Journal: J Gastrointest Surg Date: 2014-03-26 Impact factor: 3.452
Authors: Stefan Fritz; Miriam Klauss; Frank Bergmann; Thilo Hackert; Werner Hartwig; Oliver Strobel; Bogata D Bundy; Markus W Büchler; Jens Werner Journal: Ann Surg Date: 2012-08 Impact factor: 12.969
Authors: Yazan S Khaled; Muhammed Mohsin; Kavi Fatania; Ada Yee; Robert Adair; Maria Sheridan; Christian Macutkiewicz; Amer Aldouri; Andrew M Smith Journal: HPB (Oxford) Date: 2016-08-30 Impact factor: 3.647
Authors: Jeremy Sharib; Laura Esserman; Eugene J Koay; Anirban Maitra; Yu Shen; Kimberly S Kirkwood; Elissa M Ozanne Journal: Surgery Date: 2020-07-29 Impact factor: 3.982